Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

147 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Adjuvant everolimus after surgery for renal cell carcinoma (EVEREST): a double-blind, placebo-controlled, randomised, phase 3 trial.
Ryan CW, Tangen CM, Heath EI, Stein MN, Meng MV, Alva AS, Pal SK, Puzanov I, Clark JI, Choueiri TK, Agarwal N, Uzzo RG, Haas NB, Synold TW, Plets M, Vaishampayan UN, Shuch BM, Thompson IM Jr, Lara PN Jr. Ryan CW, et al. Among authors: alva as. Lancet. 2023 Sep 23;402(10407):1043-1051. doi: 10.1016/S0140-6736(23)00913-3. Epub 2023 Jul 28. Lancet. 2023. PMID: 37524096 Clinical Trial.
SWOG S0925: A Randomized Phase II Study of Androgen Deprivation Combined With Cixutumumab Versus Androgen Deprivation Alone in Patients With New Metastatic Hormone-Sensitive Prostate Cancer.
Yu EY, Li H, Higano CS, Agarwal N, Pal SK, Alva A, Heath EI, Lam ET, Gupta S, Lilly MB, Inoue Y, Chi KN, Vogelzang NJ, Quinn DI, Cheng HH, Plymate SR, Hussain M, Tangen CM, Thompson IM Jr. Yu EY, et al. J Clin Oncol. 2015 May 10;33(14):1601-8. doi: 10.1200/JCO.2014.59.4127. Epub 2015 Apr 6. J Clin Oncol. 2015. PMID: 25847934 Free PMC article. Clinical Trial.
Comparative effectiveness of gemcitabine plus cisplatin versus methotrexate, vinblastine, doxorubicin, plus cisplatin as neoadjuvant therapy for muscle-invasive bladder cancer.
Galsky MD, Pal SK, Chowdhury S, Harshman LC, Crabb SJ, Wong YN, Yu EY, Powles T, Moshier EL, Ladoire S, Hussain SA, Agarwal N, Vaishampayan UN, Recine F, Berthold D, Necchi A, Theodore C, Milowsky MI, Bellmunt J, Rosenberg JE; Retrospective International Study of Cancers of the Urothelial Tract (RISC) Investigators. Galsky MD, et al. Cancer. 2015 Aug 1;121(15):2586-93. doi: 10.1002/cncr.29387. Epub 2015 Apr 14. Cancer. 2015. PMID: 25872978 Free article.
Nivolumab versus Everolimus in Advanced Renal-Cell Carcinoma.
Motzer RJ, Escudier B, McDermott DF, George S, Hammers HJ, Srinivas S, Tykodi SS, Sosman JA, Procopio G, Plimack ER, Castellano D, Choueiri TK, Gurney H, Donskov F, Bono P, Wagstaff J, Gauler TC, Ueda T, Tomita Y, Schutz FA, Kollmannsberger C, Larkin J, Ravaud A, Simon JS, Xu LA, Waxman IM, Sharma P; CheckMate 025 Investigators. Motzer RJ, et al. N Engl J Med. 2015 Nov 5;373(19):1803-13. doi: 10.1056/NEJMoa1510665. Epub 2015 Sep 25. N Engl J Med. 2015. PMID: 26406148 Free PMC article. Clinical Trial.
Extension of overall survival beyond objective responses in patients with metastatic renal cell carcinoma treated with high-dose interleukin-2.
Stenehjem DD, Toole M, Merriman J, Parikh K, Daignault S, Scarlett S, Esper P, Skinner K, Udager A, Tantravahi SK, Gill D, Straubhar AM, Agarwal AM, Grossmann KF, Samlowski WE, Redman B, Agarwal N, Alva A. Stenehjem DD, et al. Cancer Immunol Immunother. 2016 Aug;65(8):941-9. doi: 10.1007/s00262-016-1854-1. Epub 2016 Jun 8. Cancer Immunol Immunother. 2016. PMID: 27277816 Free PMC article.
Third-line Targeted Therapy in Metastatic Renal Cell Carcinoma: Results from the International Metastatic Renal Cell Carcinoma Database Consortium.
Wells JC, Stukalin I, Norton C, Srinivas S, Lee JL, Donskov F, Bjarnason GA, Yamamoto H, Beuselinck B, Rini BI, Knox JJ, Agarwal N, Ernst DS, Pal SK, Wood LA, Bamias A, Alva AS, Kanesvaran R, Choueiri TK, Heng DY. Wells JC, et al. Among authors: alva as. Eur Urol. 2017 Feb;71(2):204-209. doi: 10.1016/j.eururo.2016.05.049. Epub 2016 Jun 16. Eur Urol. 2017. PMID: 27318422
Contemporary experience with high-dose interleukin-2 therapy and impact on survival in patients with metastatic melanoma and metastatic renal cell carcinoma.
Alva A, Daniels GA, Wong MK, Kaufman HL, Morse MA, McDermott DF, Clark JI, Agarwala SS, Miletello G, Logan TF, Hauke RJ, Curti B, Kirkwood JM, Gonzalez R, Amin A, Fishman M, Agarwal N, Lowder JN, Hua H, Aung S, Dutcher JP. Alva A, et al. Cancer Immunol Immunother. 2016 Dec;65(12):1533-1544. doi: 10.1007/s00262-016-1910-x. Epub 2016 Oct 6. Cancer Immunol Immunother. 2016. PMID: 27714434 Free PMC article.
Nomogram-based Prediction of Overall Survival in Patients with Metastatic Urothelial Carcinoma Receiving First-line Platinum-based Chemotherapy: Retrospective International Study of Invasive/Advanced Cancer of the Urothelium (RISC).
Necchi A, Sonpavde G, Lo Vullo S, Giardiello D, Bamias A, Crabb SJ, Harshman LC, Bellmunt J, De Giorgi U, Sternberg CN, Cerbone L, Ladoire S, Wong YN, Yu EY, Chowdhury S, Niegisch G, Srinivas S, Vaishampayan UN, Pal SK, Agarwal N, Alva A, Baniel J, Golshayan AR, Morales-Barrera R, Bowles DW, Milowsky MI, Theodore C, Berthold DR, Daugaard G, Sridhar SS, Powles T, Rosenberg JE, Galsky MD, Mariani L; RISC Investigators. Necchi A, et al. Eur Urol. 2017 Feb;71(2):281-289. doi: 10.1016/j.eururo.2016.09.042. Epub 2016 Oct 8. Eur Urol. 2017. PMID: 27726966 Free PMC article.
Efficacy of Second-line Targeted Therapy for Renal Cell Carcinoma According to Change from Baseline in International Metastatic Renal Cell Carcinoma Database Consortium Prognostic Category.
Davis ID, Xie W, Pezaro C, Donskov F, Wells JC, Agarwal N, Srinivas S, Yuasa T, Beuselinck B, Wood LA, Ernst DS, Kanesvaran R, Knox JJ, Pantuck A, Saleem S, Alva A, Rini BI, Lee JL, Choueiri TK, Heng DYC. Davis ID, et al. Eur Urol. 2017 Jun;71(6):970-978. doi: 10.1016/j.eururo.2016.09.047. Epub 2016 Oct 19. Eur Urol. 2017. PMID: 27771126
Venous thromboembolism in metastatic urothelial carcinoma or variant histologies: incidence, associative factors, and effect on survival.
Ramos JD, Casey MF, Crabb SJ, Bamias A, Harshman LC, Wong YN, Bellmunt J, De Giorgi U, Ladoire S, Powles T, Pal SK, Niegisch G, Recine F, Alva A, Agarwal N, Necchi A, Vaishampayan UN, Rosenberg JE, Galsky MD, Yu EY; RISC Investigators. Ramos JD, et al. Cancer Med. 2017 Jan;6(1):186-194. doi: 10.1002/cam4.986. Epub 2016 Dec 20. Cancer Med. 2017. PMID: 28000388 Free PMC article.
147 results